UK-based AI-powered biotechnology company Healx has raised USD 47 million in a Series C funding round co-led by R42 Group and Atomico, with contributions from other investors including Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h, and VU Venture Partners.
The company plans to use the funds to advance its pipeline of medicines in rare oncology, renal, and neurodevelopmental disorders. This will include its lead program, HLX-1502, aimed at treating neurofibromatosis type 1 (NF1).
The program has received clearance from the FDA to proceed with a Phase II clinical trial, expected to commence in late 2024.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.